SZSE puts an end to Changsheng Life's listing



The beleaguered Changchun Changsheng Life Sciences Co., Ltd (002680.SZ), a Chinese vaccine maker mired in the scandal over poor quality vaccines scandal, has finally faced the music. On October 8, the Shenzhen Stock Exchange (SZSE) announced the suspension of the firm's shares, forcing it into a delisting and consolidation period starting October 16, 2019. The next trading day after the period expires will see its stock delisted from the Shenzhen bourse, the first major delisting in the A shares trading history due to major illegal violations.

Changsheng Life Sciences was fined RMB 600,000 by the Securities Regulatory Commission (CSRC) in July last year, as GBI reported, due to its fraudulent freeze-dried human rabies vaccine (Vero cell) production record. Soon after, the National Medical Products Administration (NMPA) and Jilin Medical Products Administration (JLMPA) dished out a RMB 9.1 billion fine to the company, whose shares were suspended for trading on March 15 this year.

Reference:

Related news
China’s National Medical Products Administration (NMPA) released a notification in relation setting out 85 drug products that will lose their approval numbers.
The China vaccine scandal continues to rumble on.
The Shenzhen Stock Exchange (SZSE) has triggered its compulsory withdrawal mechanism in relation to vaccines manufacturer Changchun Changsheng Life Sciences Co., Ltd (002680.SZ), citing serious illegalities in the firm's operations.
Chinese vaccines manufacturer Changchun Changsheng Life Sciences Co., Ltd (002680.SZ) has felt the full force of government anger over falsifying data during product manufacturing.
China's leadership have responded to a frenzied socialmediareaction after the whiff of scandal again emanated from the country's vaccines market.
Recent news
Zulema Tomás Gonzáles, head of Peru’s Ministry of Health (MINSA), this week announced that she will pressure President Martín Vizcarra to approve through emergency decrees two draft laws aimed at improving health access.
Bayer Consumer Health opened its first Asia-Pacific R&D center, located in Qidong, Jiangsu, China.
Guillaume Corpart, managing director of hospital statistics firm Global Health Intelligence, said during an interview with the Mexico Health Review that recent changes in Mexico’s public sector are putting pressure on drug and medical supplies providers.
Shenzhen-based Ionova Life Science Co., Ltd announced a successful RMB 126 million (USD 17.8 million) in a Series A financing round, led by Lilly Asia Ventures, with DYEE Capital participating.
Swiss major Novartis and Brazil’s Oswaldo Cruz Foundation (Fiocruz) signed a memorandum of understanding (MoU) to cooperate in research and development (R&D) and education projects to combat neglected diseases such as Hansen's disease (HD), Chagas disease, malaria, and sickle cell disease.
China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP) is moving to take a sizeable stake in US-headquartered biotech OncoSec Medical Inc. An agreement has been reached for CGP to acquire 44.2% of OncoSec for USD 25 million, subject to shareholder approval, with an option to fully buy out the company within 12 months.
  • 1571120805603
  • China
The Implementation Plan for the “Two Invoices” System in Public Medical Institutions Drug Procurement” was jointly released by several ministries in Shandong, led by the Health Commission bureau, as well as the Development and Reform Commission, the Healthcare Security Administration, and others.
Analytics Snapshot


Analytics Snapshot